Cryoservice manager runs the extra mile for Cancer Research

David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London

The 145-mile Grand Union Canal Run is generally acknowledged as Britain’s longest continual race. Starting in Broad Street, Birmingham and finishing in Little Italy, London, competitors have to complete the race in 45 hours.

David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.

‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.

‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’

Bryant raised £3,350 for Cancer Research and came 16th.

Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Manufacturing

GEA opens new technology centre in Germany

The opening of the new technology centre for pharmaceutical freeze-drying systems will strengthen the supplier's position in the growing pharmaceutical applications market
Subscribe now